Hiroyuki Nomura1, Daisuke Aoki1, Hirofumi Michimae2, Mika Mizuno3, Hidekatsu Nakai4, Masahide Arai5, Motoi Sasagawa6, Kimio Ushijima7, Toru Sugiyama8, Motoaki Saito9, Hideki Tokunaga10, Maki Matoda11, Toru Nakanishi12, Yoh Watanabe12, Fumiaki Takahashi13, Toshiaki Saito14, Nobuo Yaegashi15. 1. Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan. 2. Division of Biostatistics, Department of Clinical Medicine, Kitasato University School of Pharmacy, Tokyo, Japan. 3. Department of Gynecology, Aichi Cancer Center Hospital, Aichi, Japan. 4. Department of Obstetrics and Gynecology, Kindai University Faculty of Medicine, Osaka, Japan. 5. Department of Obstetrics and Gynecology, Kitasato University School of Medicine, Kanagawa, Japan. 6. Department of Gynecology, Niigata Cancer Center Hospital, Niigata, Japan. 7. Department of Obstetrics and Gynecology, Kurume University School of Medicine, Fukuoka, Japan. 8. Department of Obstetrics and Gynecology, School of Medicine, Iwate Medical University, Iwate, Japan. 9. Department of Obstetrics and Gynecology, Jikei University School of Medicine, Tokyo, Japan. 10. Department of Gynecology, Tohoku University Hospital, Miyagi, Japan. 11. Department of Gynecology, Cancer Institute Hospital, Japanese Foundation for Cancer Research Tokyo, Japan. 12. Division of Obstetrics and Gynecology, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Miyagi, Japan. 13. Clinical Research, Innovation and Education Center, Tohoku University Hospital, Miyagi, Japan. 14. Gynecology Service, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan. 15. Department of Obstetrics and Gynecology, Tohoku University Graduate School of Medicine, Miyagi, Japan.
Abstract
IMPORTANCE: The efficacy of taxane plus platinum regimens has been demonstrated for advanced or recurrent endometrial cancer; however, it has not been assessed in postoperative adjuvant chemotherapy for endometrial cancer. OBJECTIVE: To evaluate the clinical benefit of taxane plus platinum compared with standard doxorubicin plus cisplatin as postoperative adjuvant chemotherapy in endometrial cancer. DESIGN, SETTING, AND PARTICIPANTS: In this multicenter, open-label, phase 3 randomized clinical trial, patients with endometrial cancer at high-risk stage I or II or stage III or IV that did not extend beyond the abdominal cavity and had 2 cm or greater residual tumor were included from 118 institutions in Japan from November 24, 2006, to January 7, 2011. Data was analyzed from March 15, 2017, to June 30, 2017. INTERVENTIONS: Eligible patients were randomly assigned (1:1:1) to receive 6 cycles of doxorubicin, 60 mg/m2, plus cisplatin, 50 mg/m2, on day 1; docetaxel, 70 mg/m2, plus cisplatin, 60 mg/m2, on day 1; or paclitaxel, 180 mg/m2, plus carboplatin (area under the curve, 6.0 mg/mL × min) on day 1 every 3 weeks. MAIN OUTCOMES AND MEASURES: The primary end point was progression-free survival. Secondary end points were overall survival, occurrence of adverse events, tolerability, and status of lymph node dissection. RESULTS: Among 788 eligible patients, the median (SD) age was 59 (22-74) years; 263 patients were assigned to doxorubicin plus cisplatin treatment, 263 patients to docetaxel plus cisplatin treatment, and 262 patients to paclitaxel plus carboplatin treatment. The number of patients who did not complete 6 cycles was 53 (20.1%) for the doxorubicin plus cisplatin group, 45 (17.1%) for the docetaxel plus cisplatin group, and 63 (24.0%) for the paclitaxel plus carboplatin group. Tolerability of these regimens were not statistically different. After a median follow-up period of 7 years, there was no statistical difference of progression-free survival (doxorubicin plus cisplatin, 191; docetaxel plus cisplatin, 208; paclitaxel plus carboplatin, 187; P = .12) or overall survival (doxorubicin plus cisplatin, 217; docetaxel plus cisplatin, 223; paclitaxel plus carboplatin, 215; P = .67) among the 3 groups. The 5-year progression-free survival rate was 73.3% for the doxorubicin plus cisplatin group, 79.0% for the docetaxel plus cisplatin group, and 73.9% for the paclitaxel plus carboplatin group, while the 5-year overall survival rates were 82.7%, 88.1%, and 86.1%, respectively. CONCLUSIONS AND RELEVANCE: There was no significant difference of survival among patients receiving doxorubicin plus cisplatin, docetaxel plus cisplatin, or paclitaxel plus carboplatin as postoperative adjuvant chemotherapy for endometrial cancer. Because each regimen showed adequate tolerability but different toxic effects, taxane plus platinum regimens may be a reasonable alternative to treatment with doxorubicin plus cisplatin. TRIAL REGISTRATION: UMIN-CTR identifier: UMIN000000522.
IMPORTANCE: The efficacy of taxane plus platinum regimens has been demonstrated for advanced or recurrent endometrial cancer; however, it has not been assessed in postoperative adjuvant chemotherapy for endometrial cancer. OBJECTIVE: To evaluate the clinical benefit of taxane plus platinum compared with standard doxorubicin plus cisplatin as postoperative adjuvant chemotherapy in endometrial cancer. DESIGN, SETTING, AND PARTICIPANTS: In this multicenter, open-label, phase 3 randomized clinical trial, patients with endometrial cancer at high-risk stage I or II or stage III or IV that did not extend beyond the abdominal cavity and had 2 cm or greater residual tumor were included from 118 institutions in Japan from November 24, 2006, to January 7, 2011. Data was analyzed from March 15, 2017, to June 30, 2017. INTERVENTIONS: Eligible patients were randomly assigned (1:1:1) to receive 6 cycles of doxorubicin, 60 mg/m2, plus cisplatin, 50 mg/m2, on day 1; docetaxel, 70 mg/m2, plus cisplatin, 60 mg/m2, on day 1; or paclitaxel, 180 mg/m2, plus carboplatin (area under the curve, 6.0 mg/mL × min) on day 1 every 3 weeks. MAIN OUTCOMES AND MEASURES: The primary end point was progression-free survival. Secondary end points were overall survival, occurrence of adverse events, tolerability, and status of lymph node dissection. RESULTS: Among 788 eligible patients, the median (SD) age was 59 (22-74) years; 263 patients were assigned to doxorubicin plus cisplatin treatment, 263 patients to docetaxel plus cisplatin treatment, and 262 patients to paclitaxel plus carboplatin treatment. The number of patients who did not complete 6 cycles was 53 (20.1%) for the doxorubicin plus cisplatin group, 45 (17.1%) for the docetaxel plus cisplatin group, and 63 (24.0%) for the paclitaxel plus carboplatin group. Tolerability of these regimens were not statistically different. After a median follow-up period of 7 years, there was no statistical difference of progression-free survival (doxorubicin plus cisplatin, 191; docetaxel plus cisplatin, 208; paclitaxel plus carboplatin, 187; P = .12) or overall survival (doxorubicin plus cisplatin, 217; docetaxel plus cisplatin, 223; paclitaxel plus carboplatin, 215; P = .67) among the 3 groups. The 5-year progression-free survival rate was 73.3% for the doxorubicin plus cisplatin group, 79.0% for the docetaxel plus cisplatin group, and 73.9% for the paclitaxel plus carboplatin group, while the 5-year overall survival rates were 82.7%, 88.1%, and 86.1%, respectively. CONCLUSIONS AND RELEVANCE: There was no significant difference of survival among patients receiving doxorubicin plus cisplatin, docetaxel plus cisplatin, or paclitaxel plus carboplatin as postoperative adjuvant chemotherapy for endometrial cancer. Because each regimen showed adequate tolerability but different toxic effects, taxane plus platinum regimens may be a reasonable alternative to treatment with doxorubicin plus cisplatin. TRIAL REGISTRATION: UMIN-CTR identifier: UMIN000000522.
Authors: John K Chan; Michael K Cheung; Warner K Huh; Kathryn Osann; Amreen Husain; Nelson N Teng; Daniel S Kapp Journal: Cancer Date: 2006-10-15 Impact factor: 6.860
Authors: David Cella; Helen Huang; Howard D Homesley; Anthony Montag; Ritu Salani; Koen De Geest; Roger Lee; Nick M Spirtos Journal: Gynecol Oncol Date: 2010-09-21 Impact factor: 5.482
Authors: Thomas Hogberg; Mauro Signorelli; Carlos Freire de Oliveira; Roldano Fossati; Andrea Alberto Lissoni; Bengt Sorbe; Håkan Andersson; Seija Grenman; Caroline Lundgren; Per Rosenberg; Karin Boman; Bengt Tholander; Giovanni Scambia; Nicholas Reed; Gennaro Cormio; Germana Tognon; Jackie Clarke; Tomasz Sawicki; Paolo Zola; Gunnar Kristensen Journal: Eur J Cancer Date: 2010-07-07 Impact factor: 9.162
Authors: H Nomura; D Aoki; F Takahashi; N Katsumata; Y Watanabe; I Konishi; T Jobo; M Hatae; M Hiura; N Yaegashi Journal: Ann Oncol Date: 2010-08-09 Impact factor: 32.976
Authors: John K Chan; Renata Urban; Michael K Cheung; Jacob Y Shin; Amreen Husain; Nelson N Teng; Jonathan S Berek; Joan L Walker; Daniel S Kapp; Kathryn Osann Journal: Cancer Date: 2007-06-15 Impact factor: 6.860
Authors: Paul A Vasey; Gordon C Jayson; Alan Gordon; Hani Gabra; Rob Coleman; Ronnie Atkinson; David Parkin; James Paul; Andrea Hay; Stan B Kaye Journal: J Natl Cancer Inst Date: 2004-11-17 Impact factor: 13.506
Authors: Henry M Keys; James A Roberts; Virginia L Brunetto; Richard J Zaino; Nick M Spirtos; Jeffrey D Bloss; Andrew Pearlman; Mitchell A Maiman; Jeffrey G Bell Journal: Gynecol Oncol Date: 2004-03 Impact factor: 5.482
Authors: David A Barrington; Jennifer A Sinnott; Corinne Calo; David E Cohn; Casey M Cosgrove; Ashley S Felix Journal: Gynecol Oncol Date: 2020-06-09 Impact factor: 5.482